Kura Oncology registers rBA/bioequivalence study of ziftomenib in R/R AML and MDS
Kura Oncology has registered a Phase 1 trial assessing relative bioavailability and bioequivalence of ziftomenib drug products in patients with relapsed/refractory AML or MDS.
Kura Oncology's weekly update centers on a single new trial registration.
- Kura Oncology registered "NCT07929740," a Phase 1 trial of ziftomenib in participants with NPM1-mutated relapsed/refractory AML or with relapsed/refractory AML or MDS tied to mutations associated with MEIS1 overexpression. The study is designed to evaluate the pharmacokinetics of ziftomenib drug products to inform relative bioavailability and bioequivalence assessments1, with an estimated enrollment of 126 participants and a status of not yet recruiting.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.